Christopher J Parsons

US Patent:

20090018900, Jan 15, 2009

Filed:

Jun 11, 2008

Appl. No.:

12/137506

Inventors:

JOHN F. WALDRON - LOUISVILLE KY, US
WAYNE S. LAUER - DRIPPING SPRINGS TX, US
BRIAN HOLMES - Leander TX, US
CHRISTOPHER PARSONS - AUSTIN TX, US

Assignee:

HONEYWELL INTERNATIONAL INC. - MORRISTOWN NJ

International Classification:

G06F 11/34
G07B 15/00

US Classification:

705 11, 705 13

Abstract:

A parking access control system and a method of its operation in association with a parking facility. A customer operates a call box to initiate a communications session with an attendant control device operated by an attendant. In particular, the customer requests the attendant to control an exit gate so as to enable the customer to exit the parking facility with a vehicle. In response, the attendant may input into the attendant control device one of several available predetermined override conditions, which will be logged as an override transaction entry in a database in memory. After the override condition is entered, then the exit gate will operate so as to enable the customer to exit the parking facility. The override transaction entry further may also include an identification of the attendant.

US Patent:

20120220548, Aug 30, 2012

Filed:

Feb 27, 2012

Appl. No.:

13/406106

Inventors:

BRYAN P. TOOLE - MT. PLEASANT SC, US
CHRISTOPHER H. PARSONS - CHARLESTON SC, US

Assignee:

MEDICAL UNIVERSITY OF SOUTH CAROLINA - CHARLESTON SC

International Classification:

A61K 31/728
A61P 35/00

US Classification:

514 61, 514 54

Abstract:

Compositions, methods and kits are provided for treating a cancer, tumor or pre-cancerous tissue condition resistant to a chemotherapeutic agent, the tissue condition having one or more proteins or tumorigenesis markers induced by, upregulated by or otherwise associated with virus exposure. A marker may be a receptor for, or may operatively regulate production or use of hyuronan, for example by mediating a hyaluronan-associated signal path or affecting expression of a protein or signaling pathway of the diseased tissue. A treatment composition includes a competitor of hyaluronan interactions and further includes or is co-administered with a drug, e.g., a chemotherapy agent to which the virus-associated condition would be resistant absent the hyaluronan or competitor.